Global Generic Anti-cancer Injectables Market 2022 by Company, Regions, Type and Application, Forecast to 2028

Report ID: GIR2205130001 | Category: Pharma & Healthcare | Pages: 102 | Format: PDF | Published Date: May 31,2022

Request Sample Enquiry before buying Ask For Discount

Single User-$3480.00 Multi User-$5220.00

Report Description
View Table of Contents

Report Summary

The Generic Anti-cancer Injectables market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Generic Anti-cancer Injectables market size is estimated to be worth US$  million in 2021 and is forecast to a readjusted size of USD  million by 2028 with a CAGR of  % during forecast period 2022-2028. Hospital accounting for  % of the Generic Anti-cancer Injectables global market in 2021, is projected to value USD  million by 2028, growing at a  % CAGR in next six years. While Bevacizuma segment is altered to a  % CAGR between 2022 and 2028.
Global key companies of Generic Anti-cancer Injectables include Teva, Viatris, Biocon, Amgen, and Sandoz (Novartis), etc. In terms of revenue, the global top four players hold a share over  % in 2021.
Market segmentation
Generic Anti-cancer Injectables market is split by Type and by Channel. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Channel. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
    Bevacizuma
    Rituximab
    Herceptin
    Paclitaxel
    Others
Market segment by Channel, can be divided into
    Hospital
    Retail
Market segment by players, this report covers
    Teva
    Viatris
    Biocon
    Amgen
    Sandoz (Novartis)
    Pfizer
    Qilu Pharmaceutical
    Jiangsu Hansoh
    CTTQ
    Jiangsu Hengrui
    CSPC
    Innovent Biologics
Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
    South America (Brazil, Argentina, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Generic Anti-cancer Injectables product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Generic Anti-cancer Injectables, with revenue, gross margin and global market share of Generic Anti-cancer Injectables from 2019 to 2022.
Chapter 3, the Generic Anti-cancer Injectables competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Generic Anti-cancer Injectables market forecast, by regions, type and channel, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Generic Anti-cancer Injectables research findings and conclusion, appendix and data source.

1 Market Overview
    1.1 Product Overview and Scope of Generic Anti-cancer Injectables
    1.2 Classification of Generic Anti-cancer Injectables by Type
        1.2.1 Overview: Global Generic Anti-cancer Injectables Market Size by Type: 2017 Versus 2021 Versus 2028
        1.2.2 Global Generic Anti-cancer Injectables Revenue Market Share by Type in 2021
        1.2.3 Bevacizuma
        1.2.4 Rituximab
        1.2.5 Herceptin
        1.2.6 Paclitaxel
        1.2.7 Others
    1.3 Global Generic Anti-cancer Injectables Market by Channel
        1.3.1 Overview: Global Generic Anti-cancer Injectables Market Size by Channel: 2017 Versus 2021 Versus 2028
        1.3.2 Hospital
        1.3.3 Retail
    1.4 Global Generic Anti-cancer Injectables Market Size & Forecast
    1.5 Global Generic Anti-cancer Injectables Market Size and Forecast by Region
        1.5.1 Global Generic Anti-cancer Injectables Market Size by Region: 2017 VS 2021 VS 2028
        1.5.2 Global Generic Anti-cancer Injectables Market Size by Region, (2017-2022)
        1.5.3 North America Generic Anti-cancer Injectables Market Size and Prospect (2017-2028)
        1.5.4 Europe Generic Anti-cancer Injectables Market Size and Prospect (2017-2028)
        1.5.5 Asia-Pacific Generic Anti-cancer Injectables Market Size and Prospect (2017-2028)
        1.5.6 South America Generic Anti-cancer Injectables Market Size and Prospect (2017-2028)
        1.5.7 Middle East and Africa Generic Anti-cancer Injectables Market Size and Prospect (2017-2028)
    1.6 Market Drivers, Restraints and Trends
        1.6.1 Generic Anti-cancer Injectables Market Drivers
        1.6.2 Generic Anti-cancer Injectables Market Restraints
        1.6.3 Generic Anti-cancer Injectables Trends Analysis
2 Company Profiles
    2.1 Teva
        2.1.1 Teva Details
        2.1.2 Teva Major Business
        2.1.3 Teva Generic Anti-cancer Injectables Product and Solutions
        2.1.4 Teva Generic Anti-cancer Injectables Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.1.5 Teva Recent Developments and Future Plans
    2.2 Viatris
        2.2.1 Viatris Details
        2.2.2 Viatris Major Business
        2.2.3 Viatris Generic Anti-cancer Injectables Product and Solutions
        2.2.4 Viatris Generic Anti-cancer Injectables Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.2.5 Viatris Recent Developments and Future Plans
    2.3 Biocon
        2.3.1 Biocon Details
        2.3.2 Biocon Major Business
        2.3.3 Biocon Generic Anti-cancer Injectables Product and Solutions
        2.3.4 Biocon Generic Anti-cancer Injectables Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.3.5 Biocon Recent Developments and Future Plans
    2.4 Amgen
        2.4.1 Amgen Details
        2.4.2 Amgen Major Business
        2.4.3 Amgen Generic Anti-cancer Injectables Product and Solutions
        2.4.4 Amgen Generic Anti-cancer Injectables Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.4.5 Amgen Recent Developments and Future Plans
    2.5 Sandoz (Novartis)
        2.5.1 Sandoz (Novartis) Details
        2.5.2 Sandoz (Novartis) Major Business
        2.5.3 Sandoz (Novartis) Generic Anti-cancer Injectables Product and Solutions
        2.5.4 Sandoz (Novartis) Generic Anti-cancer Injectables Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.5.5 Sandoz (Novartis) Recent Developments and Future Plans
    2.6 Pfizer
        2.6.1 Pfizer Details
        2.6.2 Pfizer Major Business
        2.6.3 Pfizer Generic Anti-cancer Injectables Product and Solutions
        2.6.4 Pfizer Generic Anti-cancer Injectables Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.6.5 Pfizer Recent Developments and Future Plans
    2.7 Qilu Pharmaceutical
        2.7.1 Qilu Pharmaceutical Details
        2.7.2 Qilu Pharmaceutical Major Business
        2.7.3 Qilu Pharmaceutical Generic Anti-cancer Injectables Product and Solutions
        2.7.4 Qilu Pharmaceutical Generic Anti-cancer Injectables Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.7.5 Qilu Pharmaceutical Recent Developments and Future Plans
    2.8 Jiangsu Hansoh
        2.8.1 Jiangsu Hansoh Details
        2.8.2 Jiangsu Hansoh Major Business
        2.8.3 Jiangsu Hansoh Generic Anti-cancer Injectables Product and Solutions
        2.8.4 Jiangsu Hansoh Generic Anti-cancer Injectables Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.8.5 Jiangsu Hansoh Recent Developments and Future Plans
    2.9 CTTQ
        2.9.1 CTTQ Details
        2.9.2 CTTQ Major Business
        2.9.3 CTTQ Generic Anti-cancer Injectables Product and Solutions
        2.9.4 CTTQ Generic Anti-cancer Injectables Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.9.5 CTTQ Recent Developments and Future Plans
    2.10 Jiangsu Hengrui 
        2.10.1 Jiangsu Hengrui Details
        2.10.2 Jiangsu Hengrui Major Business
        2.10.3 Jiangsu Hengrui Generic Anti-cancer Injectables Product and Solutions
        2.10.4 Jiangsu Hengrui Generic Anti-cancer Injectables Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.10.5 Jiangsu Hengrui Recent Developments and Future Plans
    2.11 CSPC
        2.11.1 CSPC Details
        2.11.2 CSPC Major Business
        2.11.3 CSPC Generic Anti-cancer Injectables Product and Solutions
        2.11.4 CSPC Generic Anti-cancer Injectables Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.11.5 CSPC Recent Developments and Future Plans
    2.12 Innovent Biologics
        2.12.1 Innovent Biologics Details
        2.12.2 Innovent Biologics Major Business
        2.12.3 Innovent Biologics Generic Anti-cancer Injectables Product and Solutions
        2.12.4 Innovent Biologics Generic Anti-cancer Injectables Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.12.5 Innovent Biologics Recent Developments and Future Plans
3 Market Competition, by Players
    3.1 Global Generic Anti-cancer Injectables Revenue and Share by Players (2019, 2020, 2021, and 2022)
    3.2 Market Concentration Rate
        3.2.1 Top 3 Generic Anti-cancer Injectables Players Market Share in 2021
        3.2.2 Top 10 Generic Anti-cancer Injectables Players Market Share in 2021
        3.2.3 Market Competition Trend
    3.3 Generic Anti-cancer Injectables Players Head Office, Products and Services Provided
    3.4 Generic Anti-cancer Injectables Mergers & Acquisitions
    3.5 Generic Anti-cancer Injectables New Entrants and Expansion Plans
4 Market Size Segment by Type
    4.1 Global Generic Anti-cancer Injectables Revenue and Market Share by Type (2017-2022)
    4.2 Global Generic Anti-cancer Injectables Market Forecast by Type (2023-2028)
5 Market Size Segment by Channel
    5.1 Global Generic Anti-cancer Injectables Revenue Market Share by Channel (2017-2022)
    5.2 Global Generic Anti-cancer Injectables Market Forecast by Channel (2023-2028)
6 North America by Country, by Type, and by Channel
    6.1 North America Generic Anti-cancer Injectables Revenue by Type (2017-2028)
    6.2 North America Generic Anti-cancer Injectables Revenue by Channel (2017-2028)
    6.3 North America Generic Anti-cancer Injectables Market Size by Country
        6.3.1 North America Generic Anti-cancer Injectables Revenue by Country (2017-2028)
        6.3.2 United States Generic Anti-cancer Injectables Market Size and Forecast (2017-2028)
        6.3.3 Canada Generic Anti-cancer Injectables Market Size and Forecast (2017-2028)
        6.3.4 Mexico Generic Anti-cancer Injectables Market Size and Forecast (2017-2028)
7 Europe by Country, by Type, and by Channel
    7.1 Europe Generic Anti-cancer Injectables Revenue by Type (2017-2028)
    7.2 Europe Generic Anti-cancer Injectables Revenue by Channel (2017-2028)
    7.3 Europe Generic Anti-cancer Injectables Market Size by Country
        7.3.1 Europe Generic Anti-cancer Injectables Revenue by Country (2017-2028)
        7.3.2 Germany Generic Anti-cancer Injectables Market Size and Forecast (2017-2028)
        7.3.3 France Generic Anti-cancer Injectables Market Size and Forecast (2017-2028)
        7.3.4 United Kingdom Generic Anti-cancer Injectables Market Size and Forecast (2017-2028)
        7.3.5 Russia Generic Anti-cancer Injectables Market Size and Forecast (2017-2028)
        7.3.6 Italy Generic Anti-cancer Injectables Market Size and Forecast (2017-2028)
8 Asia-Pacific by Region, by Type, and by Channel
    8.1 Asia-Pacific Generic Anti-cancer Injectables Revenue by Type (2017-2028)
    8.2 Asia-Pacific Generic Anti-cancer Injectables Revenue by Channel (2017-2028)
    8.3 Asia-Pacific Generic Anti-cancer Injectables Market Size by Region
        8.3.1 Asia-Pacific Generic Anti-cancer Injectables Revenue by Region (2017-2028)
        8.3.2 China Generic Anti-cancer Injectables Market Size and Forecast (2017-2028)
        8.3.3 Japan Generic Anti-cancer Injectables Market Size and Forecast (2017-2028)
        8.3.4 South Korea Generic Anti-cancer Injectables Market Size and Forecast (2017-2028)
        8.3.5 India Generic Anti-cancer Injectables Market Size and Forecast (2017-2028)
        8.3.6 Southeast Asia Generic Anti-cancer Injectables Market Size and Forecast (2017-2028)
        8.3.7 Australia Generic Anti-cancer Injectables Market Size and Forecast (2017-2028)
9 South America by Country, by Type, and by Channel
    9.1 South America Generic Anti-cancer Injectables Revenue by Type (2017-2028)
    9.2 South America Generic Anti-cancer Injectables Revenue by Channel (2017-2028)
    9.3 South America Generic Anti-cancer Injectables Market Size by Country
        9.3.1 South America Generic Anti-cancer Injectables Revenue by Country (2017-2028)
        9.3.2 Brazil Generic Anti-cancer Injectables Market Size and Forecast (2017-2028)
        9.3.3 Argentina Generic Anti-cancer Injectables Market Size and Forecast (2017-2028)
10 Middle East & Africa by Country, by Type, and by Channel
    10.1 Middle East & Africa Generic Anti-cancer Injectables Revenue by Type (2017-2028)
    10.2 Middle East & Africa Generic Anti-cancer Injectables Revenue by Channel (2017-2028)
    10.3 Middle East & Africa Generic Anti-cancer Injectables Market Size by Country
        10.3.1 Middle East & Africa Generic Anti-cancer Injectables Revenue by Country (2017-2028)
        10.3.2 Turkey Generic Anti-cancer Injectables Market Size and Forecast (2017-2028)
        10.3.3 Saudi Arabia Generic Anti-cancer Injectables Market Size and Forecast (2017-2028)
        10.3.4 UAE Generic Anti-cancer Injectables Market Size and Forecast (2017-2028)
11 Research Findings and Conclusion
12 Appendix
    12.1 Methodology
    12.2 Research Process and Data Source
    12.3 Disclaimer

FAQ's

What does the report cover (Scope)?

It contains all the geographic trends, and market analysis for global market

ENTER REPORT NAME TO SEARCH

Global Generic Anti-cancer Injectables Market 2022 by Company, Regions, Type and Application, Forecast to 2028

Report Summary

Table of Contents

FAQ's

What does the report cover (Scope)?